title: BMD Changes Following 2-Year Treatment of Osteoporosis by using BMK to Monitor the Dose of Bisphosphonates.
abstract: Reasons for using BMK to adjust dose for Osteoporosis patients: 1) To keep balance between bone formation and bone resorption, 2) To set balance ofboneformation to be higher than bone resorption (+10%), 3) To slightly lengthen bone life cycle. Only 127 out of 197 patients who joined the program ofusingBMKto monitor Bisphosphonate dose could complete the 2-year follow-up. The measurement ofBMK used before the treatment was compared with that ofthe 2-year follow-up by using both T-score and PR. As a result, the adjustment of the Bishosphonates given period by using BMK can better reinforce both spine and hip T-scores and PR summaries, more increasing and steadier than decreasing. It can be said that usingBMK to monitor the dose of bisphosphonates can offer balance between bone formation and bone resorption (balanced with plus and steadiness than minus). Moreover it can lengthen the bone cell life cycle more than usual (CTx = 80-100% of normal value, 0.31, in women or CTx 0.25-0.31). Besides, it helps the patients to reduce the cost oftreatment of bisphosphonate by lengthening the time of administration by up to 3-6 times.
authors.forename: Sek
authors.initials: S
authors.lastname: Aksaranugraha
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D024042:Collagen Type I / Q000097:blood*; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010455:Peptides / Q000097:blood*
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide